Bank of America initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The firm issued a buy rating and a $10.00 price target on the biotechnology company’s stock.
NBRV has been the subject of several other reports. Wedbush reiterated an outperform rating on shares of Nabriva Therapeutics in a research report on Monday, March 19th. Zacks Investment Research lowered shares of Nabriva Therapeutics from a hold rating to a sell rating in a research report on Wednesday. ValuEngine lowered shares of Nabriva Therapeutics from a sell rating to a strong sell rating in a research report on Friday, February 2nd. Morgan Stanley began coverage on shares of Nabriva Therapeutics in a research report on Wednesday, January 17th. They issued an overweight rating and a $10.00 target price for the company. Finally, Cantor Fitzgerald set a $16.00 target price on shares of Nabriva Therapeutics and gave the stock a buy rating in a research report on Friday, March 16th. Two equities research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $16.69.
NBRV stock opened at $5.51 on Wednesday. Nabriva Therapeutics has a 1 year low of $4.75 and a 1 year high of $14.10.
About Nabriva Therapeutics
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.